End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.019 AUD | +5.56% | +5.56% | -5.00% |
30/04 | Transcript : Syntara Limited, Q3 2024 Earnings Call, Apr 30, 2024 | |
10/04 | Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-5.00% | 1.43Cr | |
+38.14% | 72TCr | |
+34.28% | 59TCr | |
-4.42% | 37TCr | |
+20.07% | 33TCr | |
+2.80% | 28TCr | |
+17.02% | 24TCr | |
+9.31% | 21TCr | |
-5.07% | 21TCr | |
-0.23% | 17TCr |
- Stock Market
- Equities
- SNT Stock
- News Syntara Limited
- Pharmaxis Secures US FDA Guidance to Expand Myelofibrosis Trial